Literature DB >> 7539869

Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer.

T M Jaeger1, N Weidner, K Chew, D H Moore, R L Kerschmann, F M Waldman, P R Carroll.   

Abstract

Neovascularization of tumor tissue (tumor angiogenesis) is considered essential for tumor growth, proliferation and eventually metastasis. Microvessel density or count, a measure of tumor angiogenesis, correlates with clinical outcome in skin, breast, lung and prostate carcinomas. To determine whether an association of tumor angiogenesis and nodal metastasis exists in invasive bladder cancer, microvessel counts in 41 primary invasive stages (T2 to 4,NX,M0) bladder cancers were assessed. Microvessels were identified by immunostaining of endothelial cells for factor VIII-related antigen. Microvessels were scored in selected areas showing active neovascularization, either counting a 200 x field (0.74 mm.2) or by using a 10 x 10 square ocular grid (0.16 mm.2). The microvessel count correlated with the presence of occult lymph node metastases (p < 0.0001) by both techniques. The mean microvessel count in 27 patients without lymph node metastases was 56.2 microvessels per 200 x field (standard deviation [SD] 29.5, range 7 to 130) or 28.6 microvessels per grid (SD 14.4, range 4 to 65). The 14 patients with histologically proved lymph node metastases showed mean 138.1 microvessels per 200 x fields (SD 37.9, range 82 to 202) or 74.7 microvessels per grid (SD 14.4, range 43 to 115). Good correlation was noted between area and grid counting (r = 0.97). Tumor T stage, grade and the presence of vascular or lymphatic invasion did not correlate with the presence of lymph node metastases (p = 0.41, 0.59 and 0.26, respectively). Microvessel count may provide important information regarding the risk of occult metastasis in patients with invasive bladder carcinomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539869

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  38 in total

1.  The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

Authors:  Sophia Ran; Khalid A Mohamedali; Troy A Luster; Philip E Thorpe; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 2.  Targeting angiogenesis in bladder cancer.

Authors:  Aymen A Elfiky; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

Review 3.  Incorporating VEGF-targeted therapy in advanced urothelial cancer.

Authors:  Sujata Narayanan; Sandy Srinivas
Journal:  Ther Adv Med Oncol       Date:  2016-09-16       Impact factor: 8.168

Review 4.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Anti-angiogenesis approach to genitourinary cancer treatment.

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Update Cancer Ther       Date:  2009

6.  Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).

Authors:  W M Liu; J Y Henry; B Meyer; J B Bartlett; A G Dalgleish; C Galustian
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

7.  Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer.

Authors:  K Günther; T Radkow; M A Reymond; R Pflüger; A Dimmler; W Hohenberger; T Papadopoulos
Journal:  Int J Colorectal Dis       Date:  2003-02-08       Impact factor: 2.571

Review 8.  Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Authors:  J P Crew; T S O'Brien; A L Harris
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

9.  Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

Authors:  Arjun V Balar; Andrea B Apolo; Irina Ostrovnaya; Svetlana Mironov; Alexia Iasonos; Alisa Trout; Ashley M Regazzi; Ilana R Garcia-Grossman; David J Gallagher; Matthew I Milowsky; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

10.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.